ASCO Annual Meeting - American Society of Clinical Oncology Annual Meeting

During the American Society of Clinical Oncology Annual Meeting in Chicago, IL, Ali McBride, PharmD, BCOP, president of the Association of Community Cancer Centers, discusses how growth in the oncology space will affect how pharmacists practice.

Jorge Eduardo Cortes, MD, Deputy Chair and Professor of Medicine in the Department of Leukemia at MD Anderson Cancer Center in Houston, Texas, discusses his recommendations for pharmacists who may be counseling a patient with chronic myeloid leukemia during the American Society of Clinical Oncology Annual Meeting in Chicago, IL.

Findings presented at the 2019 ASCO meeting show venetoclax plus obinutuzumab induced deep, high, and long-lasting minimal residual disease negativity in chronic lymphocytic leukemia.

At the 2019 American Society of Clinical Oncology Annual Meeting, Michael Atkins, MD, director at the Georgetown Lombardi Cancer Center, discussed what pharmacists should know about nivolumab/ipilimumab combination therapy in advanced melanoma.

The multi-national phase 3 clinical trial on the novel drug as a treatment option for patients with advanced bladder cancer after they’ve received standard chemotherapy and immune treatments.

Updated analysis shows favorable survival outcomes with nivolumab and ipilimumab and provides evidence of long-term survival in patients with advanced melanoma.

Researchers studied the quality of life, pain, Global Health Status, and adverse effects.

A study investigates whether a high-dose of vitamin D with or without exercise is a safe, effective option to prevent bone loss.

Expanded Medicare under the Affordable Care Act nearly eliminated racial disparities in access to timely cancer treatment between African American and white patients.

The Affordable Care Act was associated with more diagnoses of early-stage ovarian cancer and more women who received timely treatment.

To elevate the burden on many patients with HER2-positive breast cancer, investigators tested whether a targeted therapy of trastuzumab emtansine plus pertuzumab would lead to a safer option than traditional therapy.

Daily servings of fruits, vegetables, and grains associated with a lower risk of death from breast cancer.

An abstract presented at the 2019 American Society of Clinical Oncology Annual Meeting showed end-of-study analysis results of the phase 3 CLEOPATRA trial.

The study evaluated the activity and tolerability of venetoclax combined with cytarabine or cytarabine/idarubicin in pediatric patients with relapsed/refractory acute myeloid leukemia.

A group of health care providers, including 17 pharmacists, indicated in a recent survey that although they believe that medical marijuana likely provides benefits for patients with cancer, less than half were comfortable recommending its use.

Specialty Pharmacy Times® is on site at the American Society of Clinical Oncology Annual Meeting to provide you with coverage of the conference in real time.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Nearly half of evaluable patients with rare central nervous system tumors, neuroblastoma, or other solid tumors had responses to entrectinib.

Lowest test dose of oxaliplatin and capecitabine was comparable to the highest dose in delaying advanced gastroesophageal cancer progression and minimizing adverse effects.

Lenalidomide found to prevent the formation of blood vessels that feed tumors, yet carries significant adverse effects.

National Cancer Institute-Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice is the first nationwide precision oncology trail for patients with cancers that have not responded to standard treatments.

ASCO is conducting a clinical trial to evaluate how different targeted cancer drugs work to find additional uses outside its FDA indication.

Patients with lung cancer who reported symptoms via Moovcare showed 1-year survival of 75%.

The highest retail prices for 23 different cancer drugs was found in the United States.

Adding temozolomide (Temodar) to chemoradiation reduced the risk of death by 33% in elderly glioblastoma patients.

Aggressive treatment approach shows promise in children with high risk brain cancer.

Choosing Wisely recommendations have not substantially changed the care received by patients in the last 30 days of life.

Women diagnosed with breast cancer who carry a BRCA mutation have up to a 50% lifetime risk of developing a second breast cancer.

Rovalpituzumab tesirine reduced tumor growth and even shrank tumors in some patients with small cell lung cancer.

Patients treated with chemotherapy and IMAB362 had a median overall survival of 16.7 months.